New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis | Business Wire
Teva offers generic Tecfidera | Drug Store News
Teva Pursues Regulatory Approval in Japan for MS Drug Copaxone
Teva Long-Term Prospects Bright, Despite Headwinds - TipRanks.com
Teva Pharmaceutical's Sales Slump 18% - WSJ
Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults | BioSpace
Teva, one of the biggest generic makers, joins the the brand-name club
High-Court-Sides-Teva-Patent
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Virtual MS Medical Forum | Neurologybytes Events
Biogen, Teva benefit as payers ease up on multiple sclerosis meddling: analyst | Fierce Pharma
In blow to Teva, UK court rules in favor of Copaxone patent challenge | The Times of Israel
TEVA stock as EU cites antitrust concerns over multiple sclerosis therapy (NYSE:TEVA) | Seeking Alpha
Skinny labels' at forefront of possible Supreme Court biopharma cases | BioWorld
Biogen sues Teva over MS generic
3rd Oral Drug to Treat MS Is Approved by the F.D.A. - The New York Times
Teva tumbles as sales and earnings underwhelm
EU Probes Teva For Blocking Rivals To Multiple Sclerosis Drug
Active Biotech and Teva remain committed to clinical development program for multiple sclerosis
Teva Pharmaceutical Industries Ltd. - How much do you know about multiple sclerosis and its symptoms? View the full infographic to learn more: https://bit.ly/3fjQVjw #MultipleSclerosis #MSConnections #MS #WorldMSDay | Facebook
Here's the Simple Reason Why Multiple Sclerosis Drugs Cost So Much | The Motley Fool
Teva reports new Copaxone data in breastfeeding mothers with relapsing multiple sclerosis | Seeking Alpha
Teva defends Copaxone from Dutch patent challenge - PMLiVE
